EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Carbohydrate Antigen 125: A Useful Marker of Congestion, Fibrosis, and Prognosis in Heart Failure with Preserved Ejection Fraction

Nassiba Menghoum, Maria Chiara Badii, Matthieu Deltombe, Sibille Lejeune, Clotilde Roy, David Vancraeynest, Agnes Pasquet, Bernhard L Gerber, Sandrine Horman, Damien Gruson, Christophe Beauloye, Anne-Catherine Pouleur

ESC Heart Failure · 2024

DOI: 10.1002/ehf2.14699 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ESC Heart Failure, 2024. Verfasst von Nassiba Menghoum und 11 weiteren Autor:innen. Beteiligte Einrichtung: Cardiovascular Department, Cliniques universitaires Saint-Luc, Brussels, Belgium. Hauptthemen laut MEDLINE: Heart Failure, CA-125 Antigen, Stroke Volume, Biomarkers. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Fonds National de la Recherche Scientifique, Fondation Saint Luc, Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Heart failure (HF) with preserved ejection fraction (HFpEF) is a disease associated with high morbidity and mortality, for which it is difficult to identify patients with the poorest prognosis in routine clinical practice. Carbohydrate antigen 125 (CA 125) has been shown to be a potential marker of congestion and prognosis in HF. We sought to better characterize HFpEF patients with high CA 125 levels by using a multimodal approach. Methods and results We prospectively enrolled 139 HFpEF patients (78 ± 8 years; 60% females) and 25 controls matched for age and sex (77 ± 5 years; 60% females). They underwent two-dimensional echocardiography, cardiac magnetic resonance with late gadolinium enhancement [including extracellular volume (ECV) measurement], and serum measurements of CA 125 level. The primary endpoint of the study was a composite of all-cause mortality or first HF hospitalization. The prognostic impact of CA 125 was determined using Cox proportional hazard models. Median CA 125 levels were significantly higher in HFpEF patients compared with controls [CA 125: 23.5 (14.5–44.7) vs. 14.6 (10.3–21.0) U/mL, P = 0.004]. CA 125 levels were positively correlated with a congestion marker [N-terminal pro-brain natriuretic peptide (NT-proBNP) levels, Pearson's r = 0.37, P < 0.001] and markers of cardiac fibrosis estimated by both ECV (Pearson's r = 0.26, P = 0.003) and fibroblast growth factor 23 levels (Pearson's r = 0.50, P < 0.001). Over a median follow-up of 49 (22–64) months, 97 HFpEF patients reached the composite endpoint. Even after adjustment for the Meta-Analysis Global Group in Chronic risk score, a CA 125 level ≥35 U/mL was still a significant predictor of the composite endpoint [hazard ratio (HR): 1.58 (1.04–2.41), P = 0.032] and more particularly of HF hospitalization [HR: 1.81 (1.13–2.92), P = 0.014]. In contrast, NT-proBNP levels were not an independent predictor.

Conclusions

CA 125 levels were significantly higher in HFpEF patients compared with controls matched for age and sex and were associated with markers of congestion and cardiac fibrosis. CA 125 levels were a strong and independent predictor of HF hospitalization in HFpEF patients. These data suggest a potential value of CA 125 as a biomarker for staging and risk prediction in HFpEF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureCA-125 AntigenStroke VolumeBiomarkersMagnetic Resonance Imaging, CineFibrosisHumansFemaleMaleAgedPrognosisProspective StudiesFollow-Up StudiesEchocardiography

Stichwörter der Autor:innen

BiomarkerCarbohydrate antigen 125Cardiac fibrosisCardiac imagingHeart failureNT‐proBNPPrognosis

Substanzen

CA-125 AntigenBiomarkers

Autor:innen und Institutionen

  • Cardiovascular Department, Cliniques universitaires Saint-Luc, Brussels, Belgium.
  • Pôle de Recherche Cardiovasculaire (CARD), Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain (UCLouvain), Brussels, Belgium.
  • Department of Laboratory Medicine, Cliniques universitaires Saint-Luc, Brussels, Belgium.

Förderung

  • Fonds National de la Recherche Scientifique
  • Fondation Saint Luc
  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung

Zitieren

APA

Menghoum, N., Badii, M. C., Deltombe, M., Lejeune, S., Roy, C., Vancraeynest, D., Pasquet, A., Gerber, B. L., Horman, S., Gruson, D., Beauloye, C., & Pouleur, A. C. (2024). Carbohydrate Antigen 125: A Useful Marker of Congestion, Fibrosis, and Prognosis in Heart Failure with Preserved Ejection Fraction. ESC Heart Failure. https://doi.org/10.1002/ehf2.14699

Vancouver

Menghoum N, Badii MC, Deltombe M, Lejeune S, Roy C, Vancraeynest D, et al. Carbohydrate Antigen 125: A Useful Marker of Congestion, Fibrosis, and Prognosis in Heart Failure with Preserved Ejection Fraction. ESC Heart Failure. 2024. doi:10.1002/ehf2.14699

BibTeX
@article{Menghoum2024,
  author = {Menghoum, Nassiba and Badii, Maria Chiara and Deltombe, Matthieu and Lejeune, Sibille and Roy, Clotilde and Vancraeynest, David and Pasquet, Agnes and Gerber, Bernhard L and Horman, Sandrine and Gruson, Damien and Beauloye, Christophe and Pouleur, Anne-Catherine},
  title = {Carbohydrate Antigen 125: A Useful Marker of Congestion, Fibrosis, and Prognosis in Heart Failure with Preserved Ejection Fraction},
  journal = {ESC Heart Failure},
  year = {2024},
  doi = {10.1002/ehf2.14699}
}
Kostenlos starten →